NASDAQ · RYTM
Rhythm Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RYTM: Nov 03, 2026
Rhythm Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.68. The reported EPS for the same quarter last year was $-0.82.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.68 | $-0.57 | $-0.80 | 8 |
| Dec 2026 | $-0.63 | $-0.45 | $-0.79 | 7 |
| Mar 2027 | $-0.51 | $-0.45 | $-0.58 | 2 |
| Jun 2027 | $-0.30 | $-0.27 | $-0.33 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest · The Motley Fool- Zacks · Oct 29, 9:00 AM EDTCAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseCAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTRhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseRhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 14, 4:53 AM EDTRhythm Launches Imcivree In Japan For Acquired Hypothalamic Obesity(RTTNews) – Rhythm Pharmaceuticals, Inc. (RYTM) announced the commercial launch of Imcivree (setmelanotide) in Japan for acquired hypothalamic obesity, following its inclusion on the country's National Health Insurance (NHI) drug price list.
- Zacks · Oct 13, 11:00 AM EDTRhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should KnowRhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- BNK Invest · Sep 29, 5:02 PM EDTRhythm Pharmaceuticals Enters Oversold Territory (RYTM)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- Zacks · Sep 18, 7:28 AM EDTUltragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- RTTNews · Aug 28, 10:42 AM EDTWeekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal(RTTNews) – This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations, and mixed clinical trial readouts.
- The Motley Fool · Aug 26, 7:05 AM EDTBillionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks — Here's What His New Positions RevealThe fund's top holding is cell-testing company Natera.
- RTTNews · Aug 24, 9:21 AM EDTRhythm Wins Japan Nod For IMCIVREE As First Treatment For Acquired Hypothalamic Obesity; Stock Up(RTTNews) – Rhythm Pharmaceuticals Inc. (RYTM), a commercial-stage biopharmaceutical company, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved IMCIVREE (setmelanotide) for the treatment of acquired hypothalamic obesity (HO).
- The Motley Fool · Aug 23, 6:20 PM EDTEli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals CanRhythm Pharmaceuticals develops medicines for rare forms of obesity.
- MarketBeat · Aug 17, 2:01 AM EDTRhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts7 Stocks That Will Drive the Weight Loss Drugs MarketRhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Offic
- RTTNews · Aug 15, 2:59 AM EDTWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals(RTTNews) – This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Rhythm Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.